SK Bioscience’s COVID-19 vaccine gets approval in UK

S.Korean COVID-19 vaccine SKYCovione will be used as a primary vaccination for people aged 18 years and over in England, Scotland, Wales

SK Bioscience’s COVID-19 vaccine gets approval in UK
1
May 30, 2023 (Gmt+09:00)
Bio & Pharma

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Monday that its domestic COVID-19 vaccine, SKYCovione, has received official marketing approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

The approval allows SKYCovione to be used as a primary vaccination for individuals aged 18 and older in the UK, Scotland and Wales. This authorization makes SKYCovione the eighth COVID-19 vaccine approved by the UK's independent medicines regulator.

SKYCovione is a synthetic antigen-based COVID-19 vaccine developed by SK Bioscience in collaboration with the Institute for Protein Design at the University of Washington School of Medicine. It was granted approval in South Korea in June of last year.

With this approval in the UK, SK Bioscience said it will seek additional authorizations such as inclusion in the World Health Organization's Emergency Use Listing (EUL) and sales authorization from the European Medicines Agency (EMA). The company aims to contribute to effective vaccination efforts during the endemic phase and ensure smooth vaccine supply to low- and middle-income countries.

Furthermore, SK Bioscience is actively pursuing the development of universal vaccines targeting SARS-CoV-2 variants and multivalent vaccines.

"Amid uncertain circumstances where the need for vaccines was questioned due to the conclusion of the COVID-19 pandemic, we have come this far with a belief in safeguarding global public health,” said Ahn Jae-Yong, SK Bioscience CEO, adding, “I am confident that this approval will be a catalyst to solidifying our global market position in the new phase of the endemic situation."

By Hyun-Ah Oh 

5hyun@hankyung.com

SK Bioscience to invest $1.8 billion, seeks M&As for inorganic growth

SK Bioscience to invest $1.8 billion, seeks M&As for inorganic growth

SK Bioscience CEO Ahn Jae-yong holds a press conference to unveil the company's strategy SK Bioscience Co., the drug-making unit of South Korea’s SK Group, plans to spend 2.4 trillion won ($1.8 billion) over the next five years and seek mergers and acquisitions to expand its business port

Phase 3 clinical plan for SK Bioscience's booster shot approved in Colombia

Phase 3 clinical plan for SK Bioscience's booster shot approved in Colombia

SK Bioscience's SKYCovione SK Bioscience Co., a leading South Korean vaccine and biotech company, announced on Monday that its phase 3 clinical trial plan for a heterogeneous booster shot of the COVID-19 vaccine, GBP510 or SKYCovione, had been approved by Colombian health authorities.GBP510 is

SK Bioscience seeks WHO nod for prompt COVID vaccine sale

SK Bioscience seeks WHO nod for prompt COVID vaccine sale

SK Bioscience’s production line of SKYCovione in South Korea (Courtesy of Yonhap) SK Bioscience Co., the biopharmaceutical unit of South Korea’s No. 2 conglomerate SK Group, sought approval from the World Health Organization (WHO) for the immediate sale of the company’s COVID-

SK Bioscience wins marketing license for Korea's first COVID-19 vaccine

SK Bioscience wins marketing license for Korea's first COVID-19 vaccine

SKYCovione, SK Bioscience's COVID-19 vaccine (Courtesy of SK Bioscience) South Korea’s SK Bioscience Co., a biopharmaceutical unit of SK Group, has won marketing authorization for its COVID-19 vaccine from the Ministry of Food and Drug Safety (MFDS) of Korea on Wednesday. MFDS approved th

K-bio firms embrace gene therapy CDMO as Samsung looks the other way

K-bio firms embrace gene therapy CDMO as Samsung looks the other way

South Korea's first homegrown COVID-19 vaccine, SKYCovione, produced by SK Bioscience South Korea’s major biopharmaceutical companies are rapidly embracing the cell and gene therapy business under a contract drug-making mechanism while Samsung Biologics Co. remains lukewarm toward the eme